Einfluss der R-CHOP Therapie auf die Verteilung und die Funktion von Immunzellen bei Patienten mit aggressivem Non-Hodgkin-Lymphom
S Zöphel - 2022 - publikationen.sulb.uni-saarland.de
Das häufig auftretende diffus großzellige B-Zell-Lymphom (DLBCL) wird als
Standardtherapie mit einer Kombination aus Chemotherapie und dem zusätzlichen Einsatz …
Standardtherapie mit einer Kombination aus Chemotherapie und dem zusätzlichen Einsatz …
[HTML][HTML] The peripheral blood lymphocyte to monocyte ratio at diagnosis is a potent outcome predictor in diffuse large B-cell lymphoma treated with R-CHOP: a long …
A Rambaldi, C Boschini, F Delaini, E Oldani, A Rossi… - Blood, 2012 - Elsevier
Abstract Abstract 1553 Background and Aim The number and type of lymphocytes and
monocytes/macrophages detectable in the peripheral blood and the lymph nodes of patients …
monocytes/macrophages detectable in the peripheral blood and the lymph nodes of patients …
[HTML][HTML] Transferability Of results from randomized trials to clinical practice: the case of diffuse large B cell lymphoma patients treated with R-CHOP when comorbidities …
Abstract Background Immuno-chemotherapy with Rituximab and CHOP (R-CHOP)
represents the standard of care for Diffuse Large B Cell Lymphoma DLBCL patients of any …
represents the standard of care for Diffuse Large B Cell Lymphoma DLBCL patients of any …
Chemoimmunotherapy with R-CHOP or high dose sequential therapy with autologous stem cell transplantation (R-HDS) for high risk diffuse large B-cell lymphomas …
Abstract Abstract Background The clinical benefit of high dose chemotherapy programs in
patients with diffuse large B cell lymphomas (DLBCL) with unfavorable presentation (IPI> 2) …
patients with diffuse large B cell lymphomas (DLBCL) with unfavorable presentation (IPI> 2) …
Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity
E Brusamolino, C Rusconi, L Montalbetti… - …, 2006 - haematologica.org
BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate the feasibility and
toxicity of CHOP-14, with rituximab (R-CHOP-14), supported by pegfilgrastim, in untreated …
toxicity of CHOP-14, with rituximab (R-CHOP-14), supported by pegfilgrastim, in untreated …
Similar effectiveness of R‐CHOP‐14 and‐21 in diffuse large B‐cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms
W Knauf, W Abenhardt, J Mohm, J Rauh… - European Journal of …, 2019 - Wiley Online Library
Objectives R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is
the standard therapy for patients with previously untreated diffuse large B‐cell lymphomas …
the standard therapy for patients with previously untreated diffuse large B‐cell lymphomas …
The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients
M Długosz‐Danecka, S Szmit, T Ogórka… - Cancer …, 2019 - Wiley Online Library
The prognosis of diffuse large B‐cell lymphoma (DLBCL) patients depends on lymphoma‐
and patient‐related risk factors and is best estimated by the international prognostic index …
and patient‐related risk factors and is best estimated by the international prognostic index …
[HTML][HTML] Impact of dose-density delays in diffuse large B-Cell Lymphoma (DLBCL) treated with R-CHOP21 or R-CHOP14
A Gutierrez, AM Bautista-Gili, L Bento, I Herraez… - Blood, 2013 - Elsevier
Background DLBCL is the more common non Hodgkin lymphoma. This is an aggressive
lymphoma that is treated with a standard chemotherapy regimen: R-CHOP. In the last years …
lymphoma that is treated with a standard chemotherapy regimen: R-CHOP. In the last years …
Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP …
LF Porrata, KM Ristow, SM Geyer, SN Markovic… - Blood, 2005 - Elsevier
Absolute lymphocyte count (ALC) recovery post-autologous stem cell transplantation has
been documented as an independent predictor for survival in non-Hodgkin lymphoma. The …
been documented as an independent predictor for survival in non-Hodgkin lymphoma. The …
Efficacy of Dose-Dense R-CHOP-14 Chemoimmunotherapy Plus Pegfilgrastim for First-Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) in Low Risk …
E Gonzalez-Barca, A Salar, J Bargay, JF Tomas… - Blood, 2007 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin
lymphoma. The addition of rituximab to the standard treatment with 3-weekly CHOP (R …
lymphoma. The addition of rituximab to the standard treatment with 3-weekly CHOP (R …